AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12151999
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg efavirenz
Trial: 30987667
Drug: Sipjeondaebo-tang (SDT)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sipjeondaebo-tang (SDT) 3 g three times daily for 8 weeks
Trial: 30987667
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 g three times daily for 8 weeks
Trial: 27893018
Drug: ω-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 PUFAs (1.4 g daily) plus CBCM
Trial: 18813219
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (0.5 mg dutasteride + 0.4 mg tamsulosin once daily)
Trial: 18813219
Drug: Dutasteride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (0.5 mg once daily)
Trial: 22561055
Drug: Oral viscous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral viscous budesonide (OVB)
Trial: 30635130
Drug: Betahistine (H3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (H3 receptor inverse agonist)
Trial: 30635130
Drug: Thioperamide (H3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioperamide (H3 receptor inverse agonist)
Trial: 19466229
Drug: APF gel
RxNorm normalized name: APF Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF gel application for 1 min
Trial: 19466229
Drug: APF gel
RxNorm normalized name: APF Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF gel application for 4 min
Trial: 16752874
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil (100 mcg)
Trial: 15223097
Drug: Conventional doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional doses of buprenorphine tapered down over 5 days
Trial: 11330408
Drug: 45 g
RxNorm normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 g of native amylomaize starch, containing 28 g of resistant starch type II
Trial: 7044709
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment group
Trial: 8387254
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion at 25 pmol/kg/min
Trial: 8387254
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion plus placebo inhalation
Trial: 8387254
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion plus albuterol inhalation (5 mg)
Trial: 8387254
Drug: ANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANP infusion (both rates)
Trial: 8387254
Drug: ANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANP infusion at 25 pmol/kg/min
Trial: 22474993
Drug: L-carnitine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine for 2 weeks before ICSI
Trial: 8903809
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg meperidine
Trial: 3113291
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg butorphanol
Trial: 15851889
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg meperidine plus 0.5 mg butorphanol
Trial: 10613728
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b (IFN) treatment (3 x 10(6), 3 times a week, for 1 year) (n = 30)
Trial: 3698513
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (ANG II) infusion for 3 hours
Trial: 3698513
Drug: Arginine vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine vasopressin (AVP) infusion for 3 hours
Trial: 28254158
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET)
Trial: 18537952
Drug: Sildenafil (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (initial dose 50 mg, adjustable to 25 or 100 mg)
Trial: 18537952
Drug: Apomorphine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (initial dose 2 mg, adjustable to 3 mg)
Trial: 18537952
Drug: Preference after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference after treatment
Trial: 12556143
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg artemether, administered orally for a total of six doses once every 4 weeks
Trial: 12556143
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered orally for a total of six doses once every 4 weeks
Trial: 12556143
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg artemether
Trial: 10659911
Drug: Estroprogestin (E/P)
RxNorm normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estroprogestin (E/P) pill (gestroden 0.75 mg and ethynlestradiol 0.03 mg) for 12 months
Trial: 10659911
Drug: Gonadotrophin releasing
RxNorm normalized name: Gonadotrophin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin releasing hormone agonist (GNRHa) (tryptorelin 3.75 mg slow release every 28 days for 4 months) followed by E/P pill for 8 months
Trial: 29869298
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg TQ Intermediate Aged
Trial: 28404841
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg daily for 6 weeks
Trial: 9484423
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg daily
Trial: 25099747
Drug: Symbiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic therapy (Group A)
Trial: 22057309
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 μg/kg before induction, additional 50-μg boluses during anesthesia
Trial: 22057309
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 μg/kg infused in 10 min before induction, 0.1 μg/kg/min during anesthesia
Trial: 22057309
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg infused in 10 min before induction, 1 μg/kg/h during anesthesia
Trial: 11078175
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg twice daily for 3 weeks
Trial: 9187896
Drug: Indigenous material
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigenous material graft (rectal fascia)
Trial: 2412002
Drug: Dextran at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran at 1 g/kg wt/24 hr for 5 days in addition to standard resuscitation and treatment
Trial: 29343142
Drug: abobotulinumtoxinA, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abobotulinumtoxinA, 500 U/2 mL dilution
Trial: 10816223
Drug: Local administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local administration of immunoglobulin G (IgG) intranasally daily for 6 months
Trial: 10816223
Drug: Placebo intranasally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intranasally daily for 6 months
Trial: 10816223
Drug: Local administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local administration of immunoglobulin G (IgG)
Trial: 8866410
Drug: rhuEPO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuEPO treatment for 1 year (Group A)
Trial: 8866410
Drug: rhuEPO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuEPO treatment for 2 years (Group B)
Trial: 8866410
Drug: rhuEPO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuEPO treatment (both groups)
Trial: 24913337
Drug: Adaptive Pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive Pacing Therapy (APT)
Trial: 8870441
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg/day
Trial: 30521699
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment according to national guidance
Trial: 19343062
Drug: Bifendate (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifendate (three times daily for 14 days)
Trial: 15325876
Drug: TSP/HEPA cleaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSP/HEPA cleaning method (high-efficiency particulate air vacuum cleaner and tri-sodium phosphate solution)
Trial: 11174679
Drug: Mandibular implant-supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular implant-supported overdenture (IOD)
Trial: 9436823
Drug: celiprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol (200 mg)
Trial: 9436823
Drug: celiprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol (200 mg and 800 mg) with atenolol
Trial: 27470233
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (bolus + 48-hr infusion)
Trial: 27470233
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical infusion volume and duration)
Trial: 26703889
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg per day
Trial: 8673750
Drug: Salt supplement
RxNorm normalized name: Sodium Chloride 454 mg / Potassium Chloride 30 mg ORAL TABLET [Thermotabs Buffered Salt Supplement]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt supplement (120 mmol/day of sodium chloride)
Trial: 1496946
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy (syrup containing iron, daily for 2 months)
Trial: 8105519
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline
Trial: 9259905
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline
Trial: 11691705
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (5 to 200 mg/day)
Trial: 7956700
Drug: Lymphokine activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphokine activated killer (LAK) cell therapy
Trial: 24849450
Drug: Dexmedetomidine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.8 µg·kg(‐1)·h(‐1) maintenance dose
Trial: 22929629
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg intravaginal Misoprostol
Trial: 20089970
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (CDA1 and CDB1) at a dose of 10 mg/kg
Trial: 10354248
Drug: Management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of patients with cataract attending a peripheral ophthalmic clinic for day-surgery
Trial: 7669489
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 200 mg m‐2
Trial: 7669489
Drug: Dideoxyinosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dideoxyinosine (ddI) 100 mg m‐2
Trial: 7669489
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ZDV 200 mg m‐2 plus ddI 100 mg m‐2
Trial: 7379451
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (50 gm as a water suspension followed by 4 doses of 17 gm at 12-hr intervals)
Trial: 31411383
Drug: Orodispersible minitablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orodispersible minitablet (ODMT) 10 x 1 mg swallowed with water
Trial: 31411383
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (RP) Renitec, 2 x 5 mg tablets swallowed with water
Trial: 18936284
Drug: Taranabant 6
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant 6 mg/day
Trial: 11179527
Drug: Single-dose of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of amiodarone (three 200-mg Cordarone tablets) after an overnight fast
Trial: 11179527
Drug: Single-dose of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of amiodarone (three 200-mg Cordarone tablets) after a standard high-fat breakfast
Trial: 9530364
Drug: Granisetron (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (40 micrograms/kg) infused for 30 minutes before CDDP infusion (standard method)
Trial: 21203878
Drug: 0.75% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% hyperbaric bupivacaine 7.5 mg
Trial: 21203878
Drug: 2% preservative-free
RxNorm normalized name: lidocaine 2% preservative-free injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% preservative-free 2-chloroprocaine 40 mg
Trial: 18471639
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of gatifloxacin in the dilating mixture
Trial: 18471639
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of moxifloxacin in the dilating mixture
Trial: 17171602
Drug: Interpersonal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal and Social Rhythm Therapy
Trial: 14623834
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral dexketoprofen trometamol
Trial: 8442438
Drug: Intermittent, cyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent, cyclic etidronate (400 mg/day for 2 weeks followed by 13 weeks free from study drug administration)
Trial: 3801827
Drug: No special
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No special treatment post-operatively (Control)
Trial: 27621610
Drug: Aclidinium/formoterol 400/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium/formoterol 400/12 µg
Trial: 28918877
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily with tenofovir disoproxil fumarate and emtricitabine
Trial: 28918877
Drug: Raltegravir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 1200 mg once daily
Trial: 19782784
Drug: Formal exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formal exercise program in addition to optimal medical therapy
Trial: 11686543
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg/day)
Trial: 6359471
Drug: Calcitonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin treatment for four weeks
Trial: 6359471
Drug: Calcitonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin treatment for over one year
Trial: 6359471
Drug: Calcitonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin treatment after discontinuation
Trial: 4011138
Drug: Hypotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic saline solution (150 mOsm/L)
Trial: 12950328
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen replacement therapy
Trial: 1442656
Drug: 50-mg/d iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg/d iron supplement and a low food-iron diet (50 FE + EX)
Trial: 1442656
Drug: Meat supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat supplement and high food-iron diet (M + EX)
Trial: 6535823
Drug: Medial epicondylectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial epicondylectomy and external decompression with steroid therapy
Trial: 25177431
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy alone
Trial: 31208376
Drug: Smartphone app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Smartphone app and TAU (treatment as usual)
Trial: 24768633
Drug: Subcutaneous (SQ)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SQ) injection of anthrax vaccine adsorbed (AVA)
Trial: 24768633
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injection of anthrax vaccine adsorbed (AVA)
Trial: 24768633
Drug: Subcutaneous (SQ)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SQ) injection of anthrax vaccine adsorbed (AVA) in obese participants
Trial: 2859047
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg)
Trial: 10226853
Drug: Transdermal NTG
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal NTG (0.6 mg/h)
Trial: 10226853
Drug: Sublingual NTG
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual NTG after 5 days of sustained transdermal NTG therapy (0.6 mg/h)
Trial: 10226853
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C (2 g)
Trial: 1860385
Drug: L-tryptophan 3.0g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan 3.0g/day for six weeks
Trial: 6617066
Drug: Amiloride (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (median dosage 15 mg/day or 5 mg per 25 mg hydrochlorothiazide)
Trial: 6617066
Drug: Hydrochlorothiazide (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (continued therapy)
Trial: 6617066
Drug: Amiloride (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (adjunctive treatment)
Trial: 28484877
Drug: Two NSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two NSAIDs (diclofenac and celecoxib) with morphine sulfate 10 mg/12 h
Trial: 28484877
Drug: Diclofenac with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac with morphine sulfate 10 mg/12 h
Trial: 26388272
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg IV midazolam (Group III)
Trial: 21127883
Drug: Intravenous glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glutathione (GSH) 100 mg/min for 30 min before CAG
Trial: 21127883
Drug: Intravenous glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glutathione (GSH)
Trial: 19843054
Drug: HP‐beta‐CD formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP‐beta‐CD formulation at 1, 10, 30 microg
Trial: 19843054
Drug: HP‐beta‐CD formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP‐beta‐CD formulation at 100 microg
Trial: 19843054
Drug: Tween formulation
RxNorm normalized name: Tween 80
DrugBank: Polysorbate 80 (DB11063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tween formulation at 100 microg
Trial: 17928994
Drug: Strict glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict glucose control group (SGC) with a blood glucose target of 4-6 mmol/l
Trial: 10806134
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg)
Trial: 8488960
Drug: 0.015-0.025 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015-0.025 mg/kg haloperidol
Trial: 29083331
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline (control)
Trial: 3318435
Drug: Nabumetone (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (1,000 mg at bedtime)
Trial: 1092727
Drug: Naproxen (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (250 mg twice daily)
Trial: 25887136
Drug: BT086 (IgM-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT086 (IgM-enriched immunoglobulin preparation)
Trial: 21586215
Drug: Adaptive oral
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive oral hygiene devices and orofacial exercise
Trial: 7750407
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg b.i.d. (total amount of 125mg) + PG05 1mg in the morning of the 3rd day